Old Web
English
Sign In
Acemap
>
authorDetail
>
Huda S. Salman
Huda S. Salman
Stony Brook University
Medicine
Follicular lymphoma
first line
Internal medicine
Oncology
3
Papers
0
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies.
2021
Journal of Clinical Oncology
Jacob D. Soumerai
Deepa Jagadeesh
Huda S. Salman
Izidore S. Lossos
Adam S. Asch
Nishitha Reddy
Vaishalee P. Kenkre
John M. Pagel
Daniel O. Persky
Farrukh T. Awan
Catherine Diefenbach
Wenying Huang
Judith Llorin-Sangalang
Igor Gorbatchevsky
Andrew D. Zelenetz
Show All
Source
Cite
Save
Citations (0)
ZANDELISIB, A PI3Kδ INHIBITOR ON INTERMITTENT SCHEDULE (IS) IN FOLLICULAR LYMPHOMA PATIENTS WHO PROGRESSED WITHIN 24 MONTHS OF FIRST‐LINE CHEMOIMUNOTHERAPY (POD24)
2021
Hematological Oncology
John M. Pagel
Nishitha Reddy
Deepa Jagadeesh
Anastasios Stathis
Adam S. Asch
Huda S. Salman
Vaishalee P. Kenkre
Jacob D. Soumerai
J. Llorin‐Sangalang
Igor Gorbatchevsky
J. Li
Andrew D. Zelenetz
Show All
Source
Cite
Save
Citations (0)
Efficacy and safety of the PI3Kδ inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24).
2021
Journal of Clinical Oncology
John M. Pagel
Nishitha Reddy
Deepa Jagadeesh
Anastasios Stathis
Adam S. Asch
Huda S. Salman
Vaishalee P. Kenkre
Jacob D. Soumerai
Judith Llorin-Sangalang
Igor Gorbatchevsky
Joanne Li
Andrew D. Zelenetz
Show All
Source
Cite
Save
Citations (0)
1